Allergische Reaktionen auf COVID-19-Impfstoffe – Evidenz und praxisorientiertes Vorgehen

Less than a year after the first detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), vaccines have been approved for routine use in numerous countries and have already been used in mass vaccination programs. Vaccines include the mRNA BNT162b2 and mRNA 1273. Allergic reactions...

Descripción completa

Detalles Bibliográficos
Autores principales: Klimek, L., Eckrich, J., Hagemann, J., Casper, I., Huppertz, J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Medizin 2021
Materias:
Arzneimitteltherapie
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7881317/
https://www.ncbi.nlm.nih.gov/pubmed/33580823
http://dx.doi.org/10.1007/s00108-021-00959-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7881317/
https://www.ncbi.nlm.nih.gov/pubmed/33580823
http://dx.doi.org/10.1007/s00108-021-00959-5

Ejemplares similares